Athens Euroclinic S.A.
- Address
- lock Available on a paid plan
Neurology and Acute Stroke Research
At Athens Euroclinic S.A., clinical research in Neurology focuses on cardiovascular diseases and urgent brain injury care, with a strong emphasis on acute ischemic stroke. These studies are designed to evaluate whether new treatments can improve recovery and functional outcomes after stroke.
- Acute ischemic stroke
- Cardiovascular disease research
- Testing treatment effectiveness for better stroke recovery
The site is contributing to research on therapies intended to support patients who arrive outside the usual treatment window, helping expand options for stroke care.
Immune System Disease Studies
Research at this hospital also covers immune system diseases, especially IgG4-related disease and primary Sjögren’s disease. These trials aim to better understand disease control, symptom improvement, and the safety and effectiveness of newer immune-targeted treatments.
- IgG4-related disease
- Primary Sjögren’s disease
- Evaluating new therapies for systemic autoimmune disease
Work in this area includes studies in both adult and pediatric populations, reflecting a broad interest in improving care across different age groups.
Metabolic and Cardiovascular Risk Research
Clinical trials at the Neurology Department include research on type 2 diabetes mellitus and its connection to serious cardiovascular outcomes. The goal is to compare treatment approaches that may lower the risk of heart attack, stroke, and other major complications in people with high cardiovascular risk.
- Type 2 diabetes mellitus
- Major cardiovascular event prevention
- Comparing treatments to improve long-term outcomes
This reflects a broader effort to study therapies that do more than control blood sugar, with attention to protecting heart and brain health as well.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Amgen Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Athens Euroclinic S.A.
lock Showing 1 of 4 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants with Primary Sjogren’s Disease with Moderate to Severe Systemic Disease Activity | Immunovant Sciences GmbH | Phase II | Recruiting | Dec 2025 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Andexanet Alfa | 1 | Unknown | 2023-08-23 | 2023-08-23 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.